PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Site Search
Showing 1 - 10 of 12 results
News
|
March 2, 2009
|
1 min read
News
|
Aug. 1, 2008
|
1 min read
News
|
Aug. 11, 2014
|
2 min read
News
|
Feb. 15, 2007
|
2 min read
News
|
Aug. 11, 2014
|
1 min read
News
|
Dec. 28, 2007
|
1 min read
News
|
March 3, 2017
|
3 min read
The Foundation seeks to advance its mission by making improvements in key areas of health equity and outcomes and diverse workforce development.
News
|
Feb. 15, 2023
|
3 min read
The Foundation’s commitment to these principles will continue to be a cornerstone of the Foundation’s work to advance our mission in 2023.
News
|
Jan. 19, 2023
|
4 min read
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
News
|
Sept. 1, 2022
|
3 min read